Navigation Links
Seambiotic USA and NASA Glenn Research Center Signed Agreement for Large Scale Microalgae Process Optimization
Date:7/6/2009

ASHKELON, Israel, July 6 /PRNewswire/ -- Seambiotic, a global leader in the development and production of marine microalgae for the nutraceutical and biofuel industries, has announced that its US subsidiary, Seambiotic USA, has entered into an agreement with NASA Glenn Research Center to develop an on-going collaborative R&D program for optimization of open-pond microalgae growth processes.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090706/352488 )

"Under a Space Act Agreement, NASA is partnering with Seambiotic USA to model growth processes for microalgae for use as aviation biofuel feedstock," said Prof. Ami Ben-Amotz, Chief Scientific Adviser to Seambiotic. "The goal of the Agreement is to make use of NASA's expertise in large scale computational modeling and combine it with Seambiotic's biological process modeling to make advances in biomass process cost reduction."

Under the Agreement, NASA Glenn and Seambiotic USA will work together to improve production processes and to study and qualify algae oil from alternative species and production processes as candidate aviation fuel at NASA's test facilities.

About NASA Glenn Research Center

The NASA John H. Glenn Research Center NASA Glenn Research Center (http://www.nasa.gov/glenn) is one of NASA's 10 field centers, empowered with the resources for developing cutting-edge technologies and advancing scientific research that address NASA's mission to pioneer the future in space exploration, scientific discovery and aeronautics research. Working in partnership with government, industry and academia, the center serves to maintain the US economy's global leadership while benefiting the lives of people around the world.

About Seambiotic USA

Seambiotic USA is a fully owned subsidiary of Seambiotic Ltd., located in Ashkelon, Israel. Seambiotic (http://www.seambiotic.com) was founded in 2003 to grow and process marine microalgae for the nutraceutical and biofuel industries. Seambiotic's research efforts include a pilot study at an Israeli Electric Corporation power station near the city Ashkelon, Israel, where various species of marine microalgae have been successfully cultivated using the power station's CO2 emissions released directly from their smokestacks; the microalgae are in turn used as feedstock for biofuel. Seambiotic technology reduces the cost of microalgae production significantly while lowering global warming by reducing industrial CO2 emissions. The company is currently in transition from the pilot plant stage to large scale industrial algae cultivation and production.

Contact: info@seambiotic.com


'/>"/>
SOURCE Seambiotic Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Iomai Chief Scientific Officer Dr. Gregory Glenn Details Development of Travelers Diarrhea Patch at Keystone Conference
2. Researchers unite to distribute quantum keys
3. Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research
4. Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
5. Stanford researchers find a quicker, cheaper way to sort isotopes
6. Nobel Laureate Lee Hartwell to Retire as President and Director of Fred Hutchinson Cancer Research Center in 2010
7. Elsevier Releases Results of Alternative Energy Research Leadership Study Identifying Top 25 Institutions Worldwide
8. OmniComm Systems Announces Acquisition of EDC Business of eResearchTechnology
9. The Lustgarten Foundation Awards Six Research Centers With Pancreatic Cancer Research Funding
10. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
11. Researchers putting a freeze on oscillator vibrations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
Breaking Biology Technology:
(Date:5/20/2016)...  VoiceIt is excited to announce its new ... By working together, VoiceIt and VoicePass will offer ... take slightly different approaches to voice biometrics, collaboration ... usability. Both ... "This marketing and technology partnership allows ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
Breaking Biology News(10 mins):